218 related articles for article (PubMed ID: 25386657)
1. Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.
D'Souza JW; Reddy S; Goldsmith LE; Shchaveleva I; Marks JD; Litwin S; Robinson MK
PLoS One; 2014; 9(11):e112376. PubMed ID: 25386657
[TBL] [Abstract][Full Text] [Related]
2. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.
Robinson MK; Hodge KM; Horak E; Sundberg AL; Russeva M; Shaller CC; von Mehren M; Shchaveleva I; Simmons HH; Marks JD; Adams GP
Br J Cancer; 2008 Nov; 99(9):1415-25. PubMed ID: 18841159
[TBL] [Abstract][Full Text] [Related]
3. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.
Gaborit N; Lindzen M; Yarden Y
Hum Vaccin Immunother; 2016 Mar; 12(3):576-92. PubMed ID: 26529100
[TBL] [Abstract][Full Text] [Related]
4. ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo.
Foreman PK; Gore M; Kobel PA; Xu L; Yee H; Hannum C; Ho H; Wang SM; Tran HV; Horowitz M; Horowitz L; Bhatt RR
Mol Cancer Ther; 2012 Jul; 11(7):1411-20. PubMed ID: 22553357
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells.
Belleudi F; Marra E; Mazzetta F; Fattore L; Giovagnoli MR; Mancini R; Aurisicchio L; Torrisi MR; Ciliberto G
Cell Cycle; 2012 Apr; 11(7):1455-67. PubMed ID: 22421160
[TBL] [Abstract][Full Text] [Related]
6. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
Schoeberl B; Faber AC; Li D; Liang MC; Crosby K; Onsum M; Burenkova O; Pace E; Walton Z; Nie L; Fulgham A; Song Y; Nielsen UB; Engelman JA; Wong KK
Cancer Res; 2010 Mar; 70(6):2485-94. PubMed ID: 20215504
[TBL] [Abstract][Full Text] [Related]
7. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.
Aurisicchio L; Marra E; Luberto L; Carlomosti F; De Vitis C; Noto A; Gunes Z; Roscilli G; Mesiti G; Mancini R; Alimandi M; Ciliberto G
J Cell Physiol; 2012 Oct; 227(10):3381-8. PubMed ID: 22213458
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
[TBL] [Abstract][Full Text] [Related]
9. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.
Schmitt LC; Rau A; Seifert O; Honer J; Hutt M; Schmid S; Zantow J; Hust M; Dübel S; Olayioye MA; Kontermann RE
MAbs; 2017 Jul; 9(5):831-843. PubMed ID: 28421882
[TBL] [Abstract][Full Text] [Related]
11. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Shin DH; Jo JY; Han JY
Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
[TBL] [Abstract][Full Text] [Related]
12. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
13. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
Lazrek Y; Dubreuil O; Garambois V; Gaborit N; Larbouret C; Le Clorennec C; Thomas G; Leconet W; Jarlier M; Pugnière M; Vié N; Robert B; Monnet C; Bouayadi K; Kharrat H; Mondon P; Pèlegrin A; Chardès T
Neoplasia; 2013 Mar; 15(3):335-47. PubMed ID: 23479511
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
15. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
[TBL] [Abstract][Full Text] [Related]
16. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
17. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration.
Lee S; Greenlee EB; Amick JR; Ligon GF; Lillquist JS; Natoli EJ; Hadari Y; Alvarado D; Schlessinger J
Proc Natl Acad Sci U S A; 2015 Oct; 112(43):13225-30. PubMed ID: 26460020
[TBL] [Abstract][Full Text] [Related]
19. Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies.
Fu W; Wang Y; Zhang Y; Xiong L; Takeda H; Ding L; Xu Q; He L; Tan W; Bethune AN; Zhou L
MAbs; 2014; 6(4):978-90. PubMed ID: 24838231
[TBL] [Abstract][Full Text] [Related]
20. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
